Target21上一些分子有了update New Drugs on the Horizon Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: Update from the registrational phase 2 TRIDENT-1 trial* Benjamin Besse, Institut Gustave Roussy, Villejuif, France Repotrectinib治疗NTRK fusion实体瘤的更新
First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors* Lipika Goyal, Massachusetts General Hospital, Boston, MA
Phase Ia/Ib dose-escalation study of ABL001 (CTX-009, Bispecific antibody targeting DLL4 and VEGF-A) as a single agent in patients with advanced solid tumors* Jeeyun Lee, Samsung Medical Center, Seoul, Korea VEGF-A x DLL4双抗CTX-009
Discovery of TAS0953/HM06, a novel next generation RET-specific inhibitor capable of inhibiting RET solvent front mutations* Isao Miyazaki, Taiho Pharmaceutical Company, Tukuba, Japan TAS0953/HM06结合RET并不填充G819侧链所指向的空间,可以有效的规避这个溶剂前段突变后引入的位阻,对Loxo-292、BLU-667耐药的大部分突变都显示较强的抑制,在G810R模型中显示出比Loxo-292、BLU-667更强的抗肿瘤效应 Discovery of mutant-selective PI3Ka and isoform-selective FGFR3 inhibitors: Insights from the Loxo Oncology at Lilly Discovery Model David M. Hyman, Loxo Oncology at Lilly, Stamford, CT Loxo展示了PI3K突变选择性抑制LOXO-783剂及FGFR3 isoform选择性抑制剂LOXO-435,主要讲下LOXO-783,一款高选择性、高血脑屏障穿透性的PI3Ka H1047R别构抑制剂 相比Alpeisib,LOXO-783更偏向抑制PI3Ka H1047R突变细胞的增殖,在PI3Ka H1047R BC的移植模型中可以显著抑制肿瘤但不引起胰岛素和C肽升高,脑内活性也高于Alpeisib 「插队」RLY-2608的开发,也是一款高选择性的PI3Ka突变别构抑制剂,可以更快的结合PI3Ka突变 体外抑制:强效的、突变和isoform选择性的抑制,包括PI3Ka激酶结构域热点突变H1047R和Helical结构域的E542K及E545K热点突变,但是对野生型PI3Ka抑制较弱,几乎不抑制其他isoform 激酶谱显示基本只抑制PI3Ka,更偏好突变型 可以看出正构抑制剂很难区分野生型和突变型,但是RLY-2608对突变体的抑制更强 对不管是携带激酶结构域还是helical结构域上突变的肿瘤株,RLY-2608都能强效的抑制AKT信号和细胞生长 体内数据显示,RLY-2608在不同突变模型对pAKT的调控呈现出剂量及暴露相关性 相比Aplelisib和GDC-077,在不同突变的多个瘤种模型中都能更显著抑制肿瘤生长 相比Aplelisib和GDC-077,RLY-2608显著降低了对血糖稳态的影响:荷瘤模型中重复给药后RLY-2608组在取得最大效应的同时胰岛素提升水平很低,在毒理模型中重复给药也没有引起高血糖 明年开临床 【LOXO-435】 Plenary Session 5: Drugging Difficult Targets Discovery and characterization of MRTX1133, a selective non-covalent inhibitor of KRASG12D James G. Christensen, Mirati Therapeutics, San Diego, CA Mirati介绍了高选择性的KRAS G12D非共价抑制剂MRTX1133的发现
在KRAS G12D突变的HPAC细胞株中,MRTX1133可以剂量依赖的下调pERK、PS6和DUSP6 MRTX1133选择性的强效抑制KRAS G12D突变的细胞株中KRAS新药和细胞生长,但对非KRAS G12D突变的细胞株中活性较低
CRISPR筛选查找联合治疗的靶点及潜在耐药机制
对G12V也有一定的抗肿瘤活性:KRAS G12V的平滑肌肉瘤体内模型中MRTX1133 300mpk BID可以引起完全缓解
Discovery and development of RAS(ON) inhibitors beyond KRAS G12C Stephen Kelsey, Revolution Medicines, Inc., Redwood City, CA 前后图不全,不好掰扯 |
|